Forgot Password?
Return to Course Listing

CME: Targeting chronic lymphocytic leukemia (CLL): Approaches to care at different stages of the disease


Activity Description / Statement of Need:

In this online, self-learning activity:

Chronic lymphocytic leukemia (CLL) is a diverse group of hematologic cancers in which B-cells accumulate in the blood, bone marrow, and lymphatic tissue, constituting as absolute lymphocytosis of mature-appearing lymphocytes with an appropriate immunophenotype. CLL is an indolent disease and often goes undetected for some time. Patients may present clinically with a range of constitutional symptoms usually range from lymphadenopathy, night sweats, weight loss, weakness, and fever. Staging systems take into account a variety of factors, including lymphadenopathy, splenomegaly, hepatomegaly, and the presence and severity of cytopenias, while a patient’s prognosis is impacted by gene mutation status and cytogenetic and chromosomal abnormalities. Both the presentation and progression of CLL vary between patients, although patients diagnosed in advanced or high-risk stages of the disease have a median survival of less than four years.

Target Audience:

The following HCPs: Medical oncologists and hematologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other healthcare professionals who commonly encounter patients with CLL.

Commercial Support Disclosure: This program is supported by an educational grant from Merck.

This activity is free of charge.

Release Date: January 20, 2023 -- Expiration Date: January 20, 2024

Faculty: Sikander Ailawadhi, MD


Faculty introduction, disclosures

Introductory content and review of CLL

  • Statistics and prognosis
  • Disease burden
  • Pre-treatment evaluation

Updates in treatment in patients with CLL

  • Early disease: observation
  • Advanced or symptomatic disease
      • Treatment goals
      • Present pharmacotherapy, clinical trial findings, and guideline updates
      • Patient and disease-related factors driving therapeutic decision-making for CLL, including genetic risk stratification and medical fitness
      • Choice of initial therapy – regimens may include:
        • Bruton tyrosine kinase inhibition
        • Bcl2 inhibition
        • A CD-20-targeting agent
        • A purine analog
        • An alkylating agent
    • Monitoring and assessment of patient response: complete remission and measurable residual disease; partial remission; progressive disease; stable disease
    • Refractory or relapsed disease
      • Consideration of previous therapy and the patient’s response to it
      • Management approach may include:
        • Bruton tyrosine kinase inhibition
        • Bcl2 inhibition
        • PI3K inhibition
        • Transplanation
        • A CD-20-targeting agent
        • A purine analog
        • An alkylating agent
  • Challenges: complications; ongoing symptoms; adherence
  • Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Recall the healthcare burden and barriers to effective identification and management of CLL.
  • Describe: present and emerging treatment options for CLL; their place or anticipated place in therapy; and risk-benefit profiles.
  • Formulate a treatment plan for a patient with CLL.


ACCME Activity #202379999


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Sikander Ailawadhi, MD, Assistant Professor of Clinical Medicine, Mayo Clinic, has received financial compensation for research and/or consulting work from Beigene, Sanofi, Takeda, BMS, GSK, Pharmacyclics, Amgen, Janssen, Astra Zeneca, Regeneron, Cellectar, Xencor, Abbvie, Ascentage.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Merck.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Myeloma bone disease: Monitoring and management

Prediction and management of bone complications in prostate cancer

Updates in the management of polyneuropathy of hereditary transthyretin amyloidosis (ATTR): Treating the condition head-on

Sickle cell disease (SCD): A focus on updates in therapy